MGTX: Graviton BioScience announces Ph1b positive results publication
Graviton BioScience said Beijing Tide Pharmaceutical published positive Ph1b trial results for GV101 (TDI01) in chronic graft versus host disease.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.